Cocrystal Pharma to Present at Two Upcoming Investor Conferences
ATLANTA, GA -- (Marketwired) -- 03/09/16 -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced that Jeffery Meckler, Chief Executive Officer, and Douglas Mayers, M.D., Chief Medical Officer, will present a corporate overview at the 28th Annual ROTH Conference and the Barclays Capital Global Healthcare Conference.
Details of the two presentations are as follows:
28th Annual ROTH Conference
Date: Monday, March 14th
Location: The Ritz-Carlton Laguna Niguel Hotel in Dana Point, California
Presentation Time: 7:00 AM PST
Barclays Capital Global Healthcare Conference
Date: Thursday, March 17th
Location: Loews Miami Beach Hotel in Miami, FL
Presentation Time: 8:00 AM EST
The presentations will be webcast live and may be accessed from the IR Calendar section of the Cocrystal website: http://ir.cocrystalpharma.com/ir-calendar. A replay of the webcast will be available on this site for 90 days following the live event.
About Cocrystal Pharma
Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (NYSE: OPK), Brace Pharmaceutical, LLC, and The Frost Group. For further information about Cocrystal, please refer to www.cocrystalpharma.com.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Cocrystal, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding development plans for licensed technologies, including the development of possible cures for Hepatitis B or Human Papilloma Virus. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the discovery of safe and effective drug candidates, conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the success of any of the described technologies in producing any drug candidate. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Cocrystal has made with the Securities and Exchange Commission.
Source: Cocrystal Pharma, Inc.
Released March 9, 2016